Evaluation of post-introduction COVID-19 Vaccine Effectiveness: Summary of interim guidance of the World Health Organization

Author(s): Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, L'Azou Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, Ortiz JR, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DRJournal: VaccinePMID: 34119350 June 2021
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine efficacy, ranging from 50-95% against symptomatic disease as the…

Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi.

Author(s): Chaguza C, Cornick JE, Andam CP, Gladstone RA, Alaerts M, Musicha P, Peno C, Bar-Zeev N, Kamng'ona AW, Kiran AM, Msefula CL, McGee L, Breiman RF, Kadioglu A, French N, Heyderman RS, Hanage WP, Bentley SD, Everett DBJournal: VaccinePMID: 28711389 August 2017
Pneumococcal infections cause a high death toll in Sub Saharan Africa (SSA) but the recently rolled out pneumococcal conjugate vaccines…

Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness.

Author(s): Yildirim I, Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, Pelton SI, T., he Massachusetts Dept. of Public Health.Journal: VaccinePMID: 28645717 July 2017
Following the introduction of pneumococcal conjugate vaccines (PCV), overall nasopharyngeal colonization rates have not changed significantly, however a dramatic and…